FDA ad­comm backs ac­cel­er­at­ed ap­proval of Sarep­ta's Duchenne gene ther­a­py in close vote

An FDA ad­vi­so­ry com­mit­tee vot­ed 8-6 on Fri­day that the ben­e­fits of Sarep­ta Ther­a­peu­tics’ gene ther­a­py for Duchenne mus­cu­lar dy­s­tro­phy out­weigh its risks, lend­ing their back­ing to ac­cel­er­at­ed ap­proval of the treat­ment.

In a day-long meet­ing, out­side ex­perts heard ar­gu­ments over whether the FDA should al­low use of Sarep­ta’s gene ther­a­py, known as SRP-9001, based on a sur­ro­gate end­point for pa­tients with Duchenne mus­cu­lar dy­s­tro­phy who are able to walk and have a con­firmed mu­ta­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER